<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338635</url>
  </required_header>
  <id_info>
    <org_study_id>URSA-1</org_study_id>
    <nct_id>NCT02338635</nct_id>
  </id_info>
  <brief_title>Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis</brief_title>
  <official_title>Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal
      dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage
      during PD still remain unclear, generation of Endoplasmic reticulum (ER) stress may be
      responsible for progressive membrane dysfunction. Ursodeoxycholic acid (URSA) is a powerful
      inhibitor of ER stress to protect peritoneal fibrosis in peritoneal dialysis in the
      investigators in-vitro study. In this study the researchers investigated the hypothesis that
      URSA protect peritoneal membrane damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ursodeoxycholic acid (URSA) is known to be relatively safe and beneficial in peritoneal
      dialysis patient at a dose of 300 mg per day. Patients will be randomly assigned to URSA and
      placebo group and prescribed according to the protocol. At 2 and 6 month, Peritoneal
      equilibrium test (PET) will be performed with blood sampling.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal membrane function</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in peritoneal membrane function (Δ D/Pcreatinine, ΔD/Purea) with peritoneal equilibrium test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residula renal function</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in estimated GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelial to Mesenchymal Transition, EMT</measure>
    <time_frame>6 months</time_frame>
    <description>Phenotypic changes of Mesothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxydative stress</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of GSH/GSSG, 8-OHdG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>End-Stage Kidney Disease</condition>
  <arm_group>
    <arm_group_label>URSA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug 1 tablet tid for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>Inhibition of ER stress (Ursodeoxycholic Acid)</description>
    <arm_group_label>URSA group</arm_group_label>
    <other_name>URSA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maintenance peritoneal dialysis at least 3 months

          -  Patients who are able and willing to understand, sign and date an informed consent
             document, and authorize access to protected health information

        Exclusion Criteria:

          -  Episode of peritonitis at least 3 months

          -  Episodes of admission due to other disease at lease 3 months

          -  Liver disease

          -  Allergic history with Ursodeoxycholic acid

          -  Nausea or vomiting after Ursodeoxycholic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hee Kang, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mina Yu, MD</last_name>
    <phone>+82-10-5096-7285</phone>
    <email>yuelizabeth@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun-Jung Kim, NR</last_name>
    <email>40739@eumc.co.kr</email>
  </overall_contact_backup>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University</investigator_affiliation>
    <investigator_full_name>Duk-Hee Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ER stress</keyword>
  <keyword>Peritoneal Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

